Podcast Episodes
Back to Search
Analysis vs Beliefs, CEO Challenges, GLP-1 Investments
2025 is set to change the industry. The new administration is poised to challenge many existing processes. The question is whether they will be based…
1 year, 6 months ago
Biopharma’s Manufacturing Push and Other 2024 Trends
Note: BioSpace is taking a break for the holidays. The next episode of The Weekly will air Jan. 8, 2025. Happy New Year!
Novo dominated headlines ove…
1 year, 6 months ago
Highlights From ASH, Lilly and Novo’s Manufacturing Boon, Momentum in Neuro, More
This week, GSK and Gilead and Arcellx presented key data at the American Society of Hematology (ASH) annual meeting as they vie for a competitive adv…
1 year, 6 months ago
Previous Investment Patterns Set to Repeat in 2025
“Cautious optimism” is circling once again as the industry approaches 2025. However, many companies are treading water, barely holding on as the mark…
1 year, 7 months ago
Biopharma’s Shopping Spree, Applied Crashes on Rejection, Skysona’s Safety Concerns, More
It’s officially holiday shopping season, and biopharma is getting into the spirit. Novartis expanded its presence in Huntington’s, paying up to $2.9 …
1 year, 7 months ago
BridgeBio’s ATTR-CM Approval, Cassava’s Alzheimer’s Failure, Trump’s Cabinet Picks, More
Biopharma had its collective deal-making hat on heading into the Thanksgiving holiday, with Roche buying Poseida for up to $1.5 billion, and Sarepta …
1 year, 7 months ago
51%: The Untapped Market
Women represent 51% of the population; not investing is a poor investment strategy. Incorporating women into leadership positions, into board rooms, …
1 year, 7 months ago
RFK Jr.’s HHS Nomination, Biogen’s Lupus Win and Leqembi Struggles, Neurogene’s Rough Month, More
President-elect Donald Trump announced last week that he would nominate prominent anti-vaxxer Robert F. Kennedy Jr. to lead the HHS. While this news …
1 year, 7 months ago
AbbVie’s Surprise Schizophrenia Flop, AstraZeneca’s China Drama, Hope in Huntington’s, More
Possibly the biggest news this week comes from the schizophrenia space, where AbbVie’s emraclidine failed two mid-stage trials. Acquired by AbbVie in…
1 year, 7 months ago
Investing in AI: Benefits, Regulatory Challenges
No discussion regarding the future is complete unless AI is incorporated.
In this episode, Konstantina Katcheves of Teva Pharmaceuticals and Sanskri…
1 year, 8 months ago